, and Enterococcus gallinarum (21) that are resistant to low levels of vancomycin and remain apparently susceptible to teicoplanin have been reported. However, the prevalence of this resistance may be underestimated because it is difficult to detect (38) . This phenotype, which is unusual since the antibiotics have the same mode of action (44) , is due to the fact that vancomycin acts as an inducer of resistance whereas teicoplanin does not (54) . Despite the low level of vancomycin resistance, the synergistic activity that vancomycin and aminoglycoside combinations usually display versus enterococci is abolished (38) . A mutant for which the vancomycin MIC was elevated (1,000 p,g/ml)
could be selected on vancomycin and remained inducible (54) .
Transferability of resistance. Resistance to high levels but not to low levels of glycopeptides is transferable to other gram-positive bacteria (24, 30, 42) . This difference may account for the relative incidences of the two resistance phenotypes. Plasmids encoding high-level resistance are related but not identical (24) , and the glycopeptide resistance determinant does not appear to be linked to other resistance genes (12, 23, 24) . They originate from different bacterial hosts that were isolated over a period of several years in distant geographic locations. Therefore, if clonal dissemination can be ruled out, we cannot discriminate between acquisition, by various replicons, of a glycopeptide resistance gene and a plasmid epidemic with DNA rearrangements associated with conjugal transfer. Certain vancomycin resistance plasmids have a broad host range that comprises enterococci, streptococci of various species, and Listeria monocytogenes (Table 2) , whereas others conjugate only among enterococci (24) . Plasmids that are non-selftransferable can be introduced by transformation into other streptococcal cells (23, 24) . However, all attempts at conjugal transfer to Staphylococcus aureus, Bacillus subtilis, and Bacillus thuringiensis remained unsuccessful (24) .
The genetic basis for low-level resistance to glycopeptides remains unknown. On the basis of lack of transfer of resistance and absence of plasmid DNA in the cells, the resistance gene(s) can be tentatively assigned to a chromosomal location (54) . Heterologous expression of high-level resistance. As in the wild strains, glycopeptide resistance in all transcipients is inducible by subinhibitory concentrations of vancomycin and teicoplanin but the levels achieved depend upon the host (Table 3 ). The level of resistance is high in E. faecalis and L. monocytogenes, intermediate in Streptococcus pyogenes and Streptococcus sanguis, and low in Streptococcus lactis (7, 24) . There is no obvious correlation between the intrinsic susceptibility of the recipient cell and the level of resistance after acquisition of the resistance determinant. (30, 42) , and the relative amount of the protein appears to be related, over a certain range, to the subinhibitory concentration of vancomycin in the growth medium (30) . Despite the natural resistance of E. coli to glycopeptides, which cannot cross the outer membrane (14), vanA, the structural gene for the resistance protein VanA, was cloned, purified, and sequenced in this host (7; Dutka-Malen et al., in press). This was made possible by using gram-negativegram-positive shuttle vectors which can replicate in both types of organisms and can be mobilized from E. coli to a great variety of gram-positive bacteria in which they allow the study of heterologous expression of foreign genes (47) . Similarly, low-level resistance in a strain of E. faecium correlated with inducible synthesis of a 39.5-kDa protein present in fractions enriched with cytoplasmic membranes (53) . The N-terminal amino acid sequence of the protein was determined, and there was no strong correlation between this sequence and N-terminal sequences of known proteins. (30) . Furthermore, glycopeptides do not inhibit cytoplasmic steps of cell wall synthesis (33) .
Glycopeptide antibiotics inhibit peptidoglycan synthesis by specifically complexing cell wall precursors that terminate N-acyl-D-alanyl-D-alanine (41, 53) . On the basis of indirect evidence provided by others (3, 42) and the structural homology between VanA and the D-alanine:D-alanine ligases of members of the family Enterobacteriaceae, two possibilities remain: protection and modification of the target. The second mechanism, as opposed to the first one, requires that VanA possess enzymatic activity.
(i) Target protection. The ligases of members of the Enterobacteriaceae exhibit high affinity toward the dipeptide they make (51) . It is therefore tempting, because of structural homology, to speculate that VanA also possesses affinity for D-alanyl-D-alanine and may thereby prevent binding of glycopeptides to molecules with N-acyl-D-alanyl-D-alanine terminal residues. In support of this mechanism, it has been shown that cell walls from induced cells resistant to high or low levels of glycopeptides and containing large quantities of the inducible protein bind less vancomycin. As opposed to similar preparations from uninduced bacteria, they prevent binding of the antibiotic to a pentapeptide ending with D-alanyl-D-alanine (3). This mechanism of resistance implies (i) that VanA is exported from the cells in contrast to the D-alanine:D-alanine ligases of enterobacteria and (ii) that binding of VanA to D-alanyl-D-alanine residues does not impair the activity of the enzymes involved in subsequent incorporation into peptidoglycan and cross-linking transpeptidation. Of note, decreased accessibility of the antibiotic-binding sites, which has not yet been found in human pathogens, was already anticipated, many years ago, as the only mechanism likely to confer resistance in laboratory-trained organisms (14) .
(ii) Target modification. Although, as mentioned above, VanA can act as a D-alanine:D-alanine ligase in E. coli (Dutka-Malen et al., in press), it could differ in substrate specificity from the enzymes of members of the Enterobacteriaceae. The enzyme might then catalyze synthesis of a dipeptide with, when part of cell wall precursors, less or no affinity for glycopeptides. Consistent with this hypothesis, it has been shown that the E. coli ligase, as well as the D-alanyl-D-alanine-adding enzyme, does not exhibit absolute specificity and can process D-alanine analogs (28) . Alternatively, VanA could modify D-alanyl-D-alanine so that the N-acyl-dipeptide no longer binds glycopeptides. In the latter mechanism, and as opposed to the synthesis of an alternate dipeptide, there is no need to turn off production of the chromosomal enzyme. Finally, it has been proposed that resistance could be due to inducible carboxypeptidase activity (3). The enzyme, which catalyzes the reaction opposite to ligation, could confer resistance since terminal D-alanine is required for binding of glycopeptides (34) . However, D-alanyl-D-alanine is the substrate for several enzymes concerned with the biosynthesis of the cell wall and any major alteration in the structure of the peptidoglycan implies a cascade of mutational events. In addition, although the basis for intrinsic resistance to glycopeptides of certain gram-positive species remains unknown, it has been shown that D-alanyl-D-alanine residues are present in the peptidoglycans of Leuconostoc and Pediococcus spp. (39) . Finally, the fact that the cell walls of induced resistant cells devoid of proteins bind vancomycin efficiently (3) suggests that target modification is not involved.
In a strain resistant to low levels of vancomycin it has been shown by affinity chromotography that there was no important change in peptidoglycan structure and that induction by vancomycin also induced resistance to autolysis and penicillin-induced lysis (54) . These two observations were interpreted as indicating that protection, rather than modification of the target, is the mechanism of glycopeptide resistance.
Dissemination of vanA and heterogeneity of genes for glycopeptide resistance. The presence of vanA in enterococci isolated in various geographic areas (France, Spain, the United Kingdom, and the United States) and resistant to high or low levels of glycopeptides was studied by DNA annealing using a probe internal to the resistance gene (12) . DNA of all isolates that were highly resistant to vancomycin and teicoplanin hybridized with the probe. No hybridization was observed with DNA of strains that were resistant to low levels of vancomycin. It therefore appears that vanA is responsible for high-level resistance in enterococci and that at least two classes of genes mediate high-and low-level glycopeptide resistance in enterococci. Comparative analy-VOL. 34, 1990 on November 6, 2017 by guest http://aac.asm.org/ Downloaded from sis of the structure and immunogenic properties of the proteins associated with the two resistance phenotypes led to similar conclusions (29) .
Origin of glycopeptide resistance. The results obtained at both the DNA and protein levels are in favor of an exogenous origin for high-level glycopeptide resistance in enterococci. The probe specific for vanA did not hybridize, even under low-stringency conditions, to susceptible strains (12) , and antiserum prepared against the 39-kDa resistance protein did not detect the protein in immunoblots of glycopeptide-susceptible strains (29) . These results contrast with the stepwise changes in susceptibility to vancomycin of Staphylococcus haemolyticus (40) which suggest an indigenous origin, by chromosomal mutations, for glycopeptide resistance in this species.
As has been proposed for other resistance mechanisms in human pathogens (5, 50) , it is conceivable that glycopeptide resistance in enterococci was acquired from glycopeptide producers. Alternatively, resistance could originate in bacteria intrinsically or usually resistant to the drugs, such as Leuconostoc, Pediococcus, and Lactobacillus spp. These gram-positive bacteria are considered opportunistic pathogens but are isolated with increasing frequency in clinical situations (8, 10, 11, 19-21, 35, 37) . Glycopeptide resistance in these microorganisms, which is expressed constitutively (29) , has been little studied, but they are susceptible to the same N-substituted vancomycin derivatives as enterococci with high-level acquired resistance (29) . However, there are marked differences in the resistance mechanisms of the two groups of bacteria (Table 1 ). In particular, the vanA probe did not hybridize to intrinsically resistant bacteria (12) and to the glycopeptide producers. Similarly, antibody raised against VanA did not detect a cross-reacting protein in members of the genera Leuconostoc, Lactobacillus, and Pediococcus (29) . The origin of acquired resistance to glycopeptides in enterococci therefore remains obscure.
Impact of glycopeptide resistance in gram-positive cocci on breakpoints for in vitro susceptibility testing. As mentioned above, glycopeptide resistance in enterococci, as well as in S. aureus (4, 40, 55) , is apparently still uncommon. However, the incidence of resistance in enterococci and streptococci may be underestimated. The ability to detect vancomycin resistance varies with the susceptibility testing method used (38) , and heterologous expression of high-level resistance depends upon the host species (Table 3) . In any case, glycopeptides which were considered to be uniformly active against enterococci, streptococci, and staphylococci should now be tested against these important human pathogens. The consequence of the emergence and subsequent spread of antibiotic resistance is to require reconsideration of breakpoints for in vitro susceptibility test methods. A study of the MIC distribution for a large number of grampositive cocci, susceptible or resistant to glycopeptides and belonging to various species of coagulase-negative staphylococci (16) and enterococci (12) , confirmed the validity of previous MICs for clinical categorization of these bacterial species (1, 26, 27) . However, determination of inhibition diameters of enterococci (12, 38, 45) led to the proposal of revised interpretive zone sizes (1, 45) . Strains with inhibition diameters of .17 mm (1) or 15 mm (45), as tested with 30-pug vancomycin or teicoplanin disks, are considered to be susceptible to glycopeptides. Vancomycin or teicoplanin MICs for enterococci with inhibition zone diameters less than these values should be determined. These tentative criteria are of practical importance since disk agar diffusion, using certain currently recommended interpretive zone sizes (26) , can fail to detect resistance (38) .
Conclusions. Vancomycin and, more recently, teicoplanin have been used increasingly for severe infections due to gram-positive bacteria and also as part of empiric therapy of febrile neutropenic patients (36) . However, because of the target specificity of glycopeptides and the universality of N-acyl-D-alanyl-D-alanine in bacterial cell wall precursors, acquired resistance to these antibiotics in Enterococcus spp. after more than three decades of use came as a surprise. The emergence of glycopeptide resistance in this bacterial genus, especially in E. faecium, is of concern because of the very few antibiotics that are active against these bacteria (25) . Moreover, since in certain strains resistance is mediated by self-transferable plasmids with a broad host range (24) , one can confidently predict dissemination of this new type of resistance to other gram-positive human pathogens (24) .
Despite rapid progress in the understanding of the genetics and biochemistry of glycopeptide resistance in enterococci, many theoretical (e.g., unicity or multiplicity of resistance biochemical mechanism[s], basis for induction, extent of resistance gene heterogeneity, and origin of resistance) and practical (e.g., true incidence and reliable in vitro detection of resistance) questions remain unanswered.
Increased selective pressure is clearly associated with the emergence of transferable glycopeptide resistance in enterococci (49) and is also responsible for recent plasmid-mediated resistance to two other major groups of antibiotics, cephalosporins in members of the family Enterobacteriaceae (43) and 5-nitroimidazoles in Bacteroides fragilis (6) . The appearance of plasmid-mediated transferable resistance to major antibiotic families stresses, once more, the necessity for more discriminate use of new drugs but also for continuous efforts to find or design antimicrobial agents. 
